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Abstract
Background: While opiate substitution therapy and injecting equipment provision (IEP) have reduced
blood-borne viruses (BBV) among people who inject drugs (PWID), some PWID continue to share injecting
equipment and acquire BBV. Psychosocial interventions that address risk behaviours could reduce BBV
transmission among PWID.
Methods: A pragmatic, two-armed randomised controlled, open feasibility study of PWID attending drug treatment or
IEP in four UK regions. Ninety-nine PWID were randomly allocated to receive a three-session manualised psychosocial
group intervention and BBV transmission information booklet plus treatment as usual (TAU) (n = 52) or information
booklet plus TAU (n = 47). The intervention was developed from evidence-based literature, qualitative interviews
with PWID, key stakeholder consultations, and expert opinion. Recruitment rates, retention in treatment, follow-
up completion rates and health economic data completion measured feasibility.
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Results: Fifty-six percent (99/176) of eligible PWID were recruited. More participants attended at least one intervention
session in London (10/16; 63%) and North Wales (7/13; 54%) than in Glasgow (3/12; 25%) and York (0/11). Participants
who attended no sessions (n = 32) compared to those attending at least one (n = 20) session were more likely to be
homeless (56 vs 25%, p = 0.044), injected drugs for a greater number of days (median 25 vs 6.5, p = 0.019) and used a
greater number of needles from an IEP in the last month (median 31 vs 20, p = 0.056). No adverse events were
reported. 45.5% (45/99) were followed up 1 month post-intervention. Feedback forms confirmed that the intervention
was acceptable to both intervention facilitators and participants who attended it. Follow-up attendance was associated
with fewer days of injecting in the last month (median 14 vs 27, p = 0.030) and fewer injections of cocaine (13 vs 30%,
p = 0.063). Analysis of the questionnaires identified several service use questionnaire categories that could be excluded
from the assessment battery in a full-randomised controlled trial.
Conclusions: Findings should be interpreted with caution due to small sample sizes. A future definitive RCT of the
psychosocial intervention is not feasible. The complex needs of some PWID may have limited their engagement in the
intervention. More flexible delivery methods may have greater reach.
Trial registration: ISRCTN66453696
Keywords: Blood-borne virus transmission, People who inject drugs, Feasibility randomised controlled trial,
Psychosocial interventions, Focus group research
Background
Studies report the prevalence of Hepatitis C virus (HCV)
among people who inject drugs (PWID) ranges from 5
to 90% [1] and the prevalence of HIV ranges from <1 to
50% [2]. In the UK, HCV is the most prevalent blood-
borne virus (BBV) among PWID, with 23–61% being
HCV positive [1, 3]; the rates of human immunodefi-
ciency virus (HIV) and hepatitis B (HBV) among PWID
in the UK are much lower, 0–1.4% for HIV and 6–18%
for HBV [3] preventing the transmission of BBV among
PWID thus remains a major public health issue.
While HBV and HIV are transmitted via blood or body
fluids, the greatest risk of HCV transmission among
PWID is via blood from sharing needles and other injec-
tion paraphernalia [4, 5]. Advances have been made in
treatment and pre-exposure prophylaxis for HIV [6, 7],
and a vaccine is available for HBV [8]; however, there is
currently no vaccine available to prevent HCV infection.
Opiate substitution therapy and injecting equipment
provision (IEP) have been shown to be effective in reducing
HIV and HCV among PWID [9–12]; and psychosocial in-
terventions (such as brief interventions, motivational inter-
viewing, cognitive behavioural therapy and contingency
management) could further decrease BBVs [10] by educat-
ing PWID about transmission risks and developing strat-
egies to avoid them.
Research suggests there is a gap in knowledge among
PWID regarding HCV transmission which is contribut-
ing to the high prevalence [13–15], among both new
and longer term injectors. PWID with mental health
issues report greater sharing of injection equipment,
lower rates of condom use, multiple sexual partners, sex
trading and having sex with PWID [16–19].
Public Health England’s Shooting Up report [20]
highlighted that in 2015 in England, Wales and Northern
Ireland, sharing of needles in the previous month was
reported by 16% of individuals attending drug treatment
services, in Scotland this figure was 15% in 2014–2015. The
report highlighted that the sharing of mixing containers
and filters was almost twice as common as the sharing of
needles and syringes. A large UK survey has also identified
an increased risk of infection for those who inject amphet-
amines and amphetamine-type drugs, such as mephedrone
[21]. Therefore, reducing BBV transmission risk behaviours
among PWID remains a priority.
A recent meta-analysis found that interventions using
strategies that combined substance-use treatment and
support for safe injection were most effective at reducing
HCV seroconversion [22]. A number of recent systematic
reviews of psychosocial interventions (e.g. skills training,
peer-education training and counselling) compared to lesser
interventions or educational interventions to reduce HIV
and HCV injecting and sexual risk behaviours among
PWID have reported modest effects [23, 24], conclud-
ing that future research should determine whether
these interventions work better for particular groups of
drug users [23] and that “multi-component interven-
tions are required” [24].
A psychosocial intervention (the PROTECT interven-
tion) to reduce BBV transmission risk behaviours and
increase BBV transmission knowledge among PWID
was developed, and a feasibility randomised controlled
trial (RCT) comparing the psychosocial intervention to
an information leaflet, to demonstrate the feasibility
and acceptability of delivering the intervention in harm
reduction settings throughout the UK was conducted.
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Methods
Study design
A pragmatic, two-armed, randomised controlled, open
feasibility study in which a psychosocial group (brief )
intervention was compared to treatment as usual (TAU)
plus information leaflets, on reducing the BBV transmis-
sion risk behaviours for PWID aged ≥18 years. Ethical
approval was granted by the National Research Ethics
Committee East Midlands-Leicester South Research Ethics
Committee (Reference: 15/EM/0413). Local Research and
Development (R&D) approval was obtained, as was agree-
ment to participate from the relevant services.
Setting
The trial was conducted in four locations across the UK:
in England (London, York), Wales (North Wales) and
Scotland (Glasgow). A mix of urban and semi-rural com-
munity services/sites were included to ensure different
modes of service delivery were represented:
1. London: Three Drug and Alcohol Treatment
Services providing services including advice and IEP
and treatment to people, aged over 18, who have
drug- and/or alcohol-related problems, including a
prescribing clinic within a hostel for homeless
people. The intervention was delivered at one Drug
and Alcohol Treatment Service.
2. York: Participants were recruited, and the intervention
was scheduled to be delivered at a city centre substance
use treatment service providing counselling and advice,
IEP, condoms, assessment and referral to residential
rehabilitation, specialist drug units and other agencies
providing treatment for addiction and BBV testing.
3. Glasgow: Participants were recruited from and the
intervention delivered in a drugs treatment service in
the city centre which provides both treatment and IEP.
4. North Wales: Participants were recruited from a
drug service, a drop-in centre and IEP for homeless
people and a mobile harm reduction service for
PWID not currently engaged in treatment. The
intervention was delivered at the drop-in centre and
IEP for homeless people.
Participants
Identification, eligibility and consent
Potential participants were approached by researchers in
the waiting rooms of participating services and given a
Participant Information Sheet that was also explained
to them verbally. Key workers and IEP workers also
referred eligible clients to the researchers. In addition,
flyers were distributed and posters were displayed in
the services, inviting interested participants to contact the
researcher for more details about the study. All interested
clients were screened for eligibility. Clients were eligible if
they were aged ≥18 years, had injected drugs (other than
performance enhancing drugs) at least once in the past
4 weeks, planned to stay in the area for the next 3 months,
were able to complete the assessments (all assessments
were researcher administered) and could communicate in a
group intervention in English. They were excluded if they
were too intoxicated to give informed consent or were no-
ticeably in withdrawal. If eligible and interested, written in-
formed consent was obtained.
Outcome Measures
Self-reported age, recent drug use, length of injecting
career, drug treatment history, HIV and Hepatitis C status
and vaccination against Hepatitis B were recorded.
Recruitment and acceptability
Recruitment rates (i.e. number agreeing to participate/
number eligible), retention in treatment (number of ses-
sions attended) and follow-up questionnaires completion
rates measured feasibility. Acceptability to participants was
ascertained through feedback forms and separate focus
group discussions with participants and facilitators.
Patient-reported outcomes
Participants received £10 cash (London) or £10 gift voucher
(York, Glasgow, North Wales) for time involved in com-
pleting baseline and follow-up questionnaires. Travel reim-
bursement was available in London and North Wales.
Demographic data were collected at baseline, and the fol-
lowing outcome measures were collected at baseline, at the
end of intervention and 1 month post-intervention (inter-
vention arm), and equivalent time period for control arm:
Injecting risk behaviours and self-efficacy
Nine injecting risk behaviours were assessed during the
past 28 days (including passing any needles or syringes,
cleaned needles or syringes, spoons or containers for
mixing, or filters to someone else after using them; using
any needle or syringes, cleaned needles or syringes, spoons
or containers for mixing, or filters previously used by
someone else; sharing rinse water) that may have exposed
them to BBV in the previous month were assessed using
questions from Public Health England’s survey of
PWID [3]. Events were summed to a total ranging
from 0 (engaged in no risk events) to 9 (engaged in all of
the risk events). Participants indicated agreement with
eight self-efficacy questions around injecting behaviours,
e.g. “I can avoid sharing a needle even if I am in with-
drawal”, around injecting skills (including finding a vein,
sharing equipment, cleaning equipment and talking about
safe drug use) [25]. Agreement was rated between 1
(absolutely cannot) and 4 (absolutely can), with total
scores between 8 (low self-efficacy) and 32 (high
self-efficacy) [25].
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Sexual risk behaviours
Having had sex with more than one partner in the past
month, not always having used a condom when having
sex in the past month, four items assessed whether
participants were not “absolutely sure” they would use
a condom in a given situation (sex with a regular partner,
even if they do not want to use one or participant had
been using alcohol or drugs; sex with a casual partner,
even if they do not want to use one or participant had
been using alcohol or drugs) and one question on
whether they would be able to talk about safe sex
with sexual partners they did not know. These seven
items were summed to a total ranging from 0 (no risk
behaviours) to 7 (all risk behaviours).
Withdrawal Prevention Tactics scale
This five-item scale asked whether participants had
done any of four listed tactics to avoid withdrawal
episodes: saved a bag for the next morning, put aside
additional drugs, stored methadone or put aside money
for getting the next bag in an emergency [26]. A fifth
item asked about use of other substances, such as
painkillers, to avoid withdrawal symptoms until they
are able to obtain their drug of choice. The frequency
of undertaking each withdrawal activity in the past
month were collected with responses ranging from 0
(never) to 4 (very often). The total score ranged from 0
(never taken any of the preventative actions) to 20
(taken preventative actions very often for all of the
activities).
BBV transmission knowledge
Participants rated 14 statements about HIV transmission
[27], 31 about HCV transmission [28, 29] and 15 about
HBV [30]. The total number of correct answers across
each BBV transmission questionnaire was summed
(range 0–14 for HIV, 0–31 for HCV and 0–15 for HBV).
Motivation to change behaviour
Participants were asked to rate their motivation from 1
(not at all motivated) to 5 (extremely motivated) to
protect themselves and others from acquiring BBV.
Health-related quality of life (HRQoL)
The European quality of life-5 dimensions-5 levels
(EQ-5D-5L) characterised health on five dimensions
(mobility, self-care, ability to undertake usual activities,
pain, anxiety/depression) [31].
Health and social resource used
Hospital and primary health care services use, drug
service use, other health-related services, contact with
the police and criminal justice system, and medications
prescribed in the past month were recorded.
Sample size
We aimed to recruit a total of 128 participants (64 in
intervention group) from harm reduction services in 4
locations (Glasgow, London, York and North Wales),
exceeding that recommended for feasibility studies of
between 24 and 50 [32–34] and allowed feasibility as-
sessments within both community clinics and IEP.
Randomisation process
Treatment allocation was performed by a secure, remote,
telephone randomisation service based at the University
of York. Participants were randomised by stratified block
randomisation, ensuring balanced allocation within each
location, setting (community drug service or IEP) and
gender. Participants were randomised to either:
 The psychosocial group intervention, information
booklets plus TAU or
 The control arm: information booklets plus TAU only
Intervention and comparator
The PROTECT intervention was co-developed by ser-
vice users, service providers, policy makers and aca-
demics based on an evidence-based literature, qualitative
interviews with PWID, consultation with key stake-
holders and expert opinion. The PROTECT manual
is available for download free of charge via: https://
www.kcl.ac.uk/ioppn/depts/addictions/research/drugs/
bloodborneviruses.aspx. The manualised psychosocial
group intervention consisted of three, one hour sessions
(preferably, one a week for three consecutive weeks).
Session 1 covered improving injection skills and good
vein care. Session 2 covered planning for risk situations.
Session 3 provided information about blood-borne vi-
ruses and transmission risk behaviours. Sessions used vid-
eos, games and exercises to facilitate discussion and build
skills and strategies to reduce and avoid risk. All sessions
also included a didactic education section. Separate
groups were held for women and men.
The structure of drug treatment services was different
across the settings in the study; the precise job role of
the health care professionals who conducted the groups
thus varied. However, in all settings, groups were facili-
tated by professionals with considerable experience of
working with PWID and BBV. Training took place with
all facilitators in London over 1 day and was co-delivered
by a clinician and peer educator. Following training, inter-
vention delivery varied across sites to reflect current service
provision: London—the group was co-facilitated by a drug
worker and peer educator (gender of co-facilitators
matched that of the gender of the group); Glasgow—groups
were co-facilitated by one male drug worker and one
female project co-ordinator; North Wales—the groups were
co-facilitated by one male and one female drug worker; and
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York—the groups were due to be delivered by one male
nurse specialising in BBV prevention and treatment. Con-
tingency management was used to retain participants in the
intervention [35]. Participants allocated to the intervention
arm received £10 cash (London) or £10 gift voucher
(Glasgow and North Wales) for each of the three ses-
sions attended. A “bonus” of £10 cash (London) or £10
gift voucher (Glasgow and North Wales) was given to
those who attended all three sessions.
Intervention evaluation/fidelity All sessions were ob-
served by at least one researcher to assess the feasibility
of the quality assurance methods proposed for the main
trial, including acceptability to drug worker/nursing staff
and service users. A brief checklist was used to identify
what aspects of the intervention manual were imple-
mented. At the end of each session, facilitators and par-
ticipants rated the session using an evaluation form
developed for the study.
Control
Participants in both arms received TAU from the service
from which they were recruited and a booklet containing
information on Hepatitis C (“Hep C Info: Understanding
hepatitis C and staying safe” http://ljwg.org.uk/ljwg-tool
kit/resources/) and a one-page information sheet devel-
oped specifically for the trial about a recent HIV out-
break among PWID.
Analyses
All analyses were conducted using Stata Version 13.1.
Feasibility parameters were reported descriptively and
participant flow is illustrated with a flow diagram [Fig. 1:
Study flow diagram]. Following observed differences in
compliance and follow-up at the four sites, population
characteristics for these groups were compared using
Fisher’s Exact and Wilcoxon rank-sum tests. As a feasi-
bility trial, the study was not powered for formal testing
of intervention effectiveness; however, group differences
for selected outcome measures were explored as follows.
Longitudinal regression analyses for each outcome at the
two follow-up points were conducted, adjusting for
baseline values, gender and recruitment site. Estimated
mean treatment group differences from these analyses
are presented by intention to treat (ITT) and per protocol
groups together with 80 and 95% confidence intervals.
The economic analysis included intervention costing,
calculation of NHS and wider social costs per patient,
EQ-5D-5 L results and assessment of the pilot question-
naires. Quantities of service use recorded were multiplied by
national average unit costs of health care and criminal just-
ice contacts to derive a health care cost (price year 2014/5).
Follow-up costs were defined by summing costs at the end
of the intervention and one month post-intervention.
Results
Feasibility parameters
Feasibility was assessed as the proportion of patients
consented and randomised, as well as compliance with
the intervention and attrition throughout follow-up.
The flow of participants is shown in Fig. 1 [Fig. 1:
Study flow diagram]. Of 176 eligible people who injected
drugs, 99 (56%) individuals were randomised into the
feasibility trial during January and February 2016. One
person was mistakenly randomised twice (therefore, 100
randomisations); their second randomisation was subse-
quently withdrawn.
It was not possible to compare those who were eligible
that did and did not agree to participate. The eligibility
question asked whether potential participants had injected
drugs in the previous month. If they had, researchers
discussed the study with potential participants and what
taking part involved. Seventy-seven of the 176 eligible par-
ticipants (44%) did not take part as they were not inter-
ested, too busy, entering rehabilitation treatment, too ill to
participate, unavailable to attend interventions, not wishing
others to know about their injecting, declined without rea-
son, or were uncontactable or did not attend their baseline
appointment.
Fifty-two were allocated to the intervention arm and
47 allocated to control. A total of 20 participants attended
at least one intervention session, and just under half of par-
ticipants were followed up until 1 month post-intervention.
Two female participants in London were in hospital, one
male participant was in prison in North Wales, and in
Glasgow, three female and three male participants were
in residential rehabilitation, one male participant was in
prison and one male participant was in hospital. It was
not possible to conduct follow-up interviews with those
participants.
Attendance for at least one intervention session was
highest in London (63%) and North Wales (54%),
whereas only 25% attended in Glasgow, and no partici-
pants attended in York. Follow-up at a minimum of one
time point (at the end of the intervention or one month
post-intervention) was also highest in London (83%) and
North Wales (63%) and significantly lower in Glasgow
(55%) and York (43%). Overall, men were more likely to
attend at least one intervention session (44 versus 28%).
Women were more likely to attend follow-up in London
(85%) than in York (38%), North Wales (38%) and Glas-
gow (17%).
Baseline characteristics
Overall, participants were predominantly male, in their
late 30s/early 40s with a mean injecting history of between
14 and 21 years (data aggregated by gender). Baseline
characteristics of the trial population by allocation and sex
are presented in Table 1. Baseline characteristics were
Gilchrist et al. Harm Reduction Journal  (2017) 14:14 Page 5 of 15
comparable between randomised treatment groups for
males, despite the relatively small number of participants.
The smaller group of women showed potential imbal-
ances, e.g. a greater number of heroin users and homeless
women in the intervention arm.
Compared to those who attended at least one inter-
vention session (n = 20), those who did not attend any
sessions (n = 32) were more likely to be homeless (56 vs
25%, p = 0.044), have injected drugs for a greater number
of days in the last month (median 25 vs 6.5, p = 0.019)
and used a greater number of needles from an IEP in
the last month (median 31 vs 20, p = 0.056). They were
more likely to be predominant heroin injectors (69 vs
40%, p = 0.055 for type of drug) and less likely to inject
crack (31 vs 55%, p = 0.146) [Additional file 1]. Glasgow
and York had higher levels of homelessness (68 and 52%
respectively) compared to London (27%) and North
Wales (29%). In addition, participants injected for a
greater number of days and used more needles from an
IEP [Additional file 2].
Fig. 1 Study flow diagram
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Follow-up attendance (at one or both time points) was
associated with fewer days of injecting drugs in the last
month (median 14 vs 27, p = 0.030) and fewer injections
of cocaine (13 vs 30%, p = 0.063).
Outcome measures
Outcome measures are summarised by randomised allo-
cation in Table 2 (total) and Table 3 (compliance).
The summary of group differences based on the explora-
tory longitudinal regression analyses for each outcome
(Table 4) revealed improved (fewer) injecting risk practices,
improved self-efficacy, better hepatitis C and hepatitis B
transmission knowledge and greater use of withdrawal pre-
vention techniques in the intervention arm. Little change
for any group was seen for HIV transmission knowledge. A
number of results appeared counterintuitive. Participants in
the randomised intervention group engaged in a greater
number of sexual risk behaviours at both follow-up time
points, although group differences were reduced to minimal
in the attendance-based analysis. Motivation to change was
highly skewed, with most participants indicating being
highly motivated.
Sample sizes were too small to investigate possible in-
teractions with baseline characteristics and outcomes,
e.g. whether score changes can only be seen in a subset
of the participant population.
All outcome measures were reviewed with regard to
the number of missing items that contribute to each out-
come. Overall, data completeness was very high across
all questionnaires responses, and most items were only
missing sporadically.
At 1 month post-intervention, no increase in self-reported
injecting in more “risky” sites (e.g. groin, neck) was observed
among participants who had attended at least one session of
the intervention. A trend towards injecting on fewer days in
the past 28 days for those who had attended at least one
session at 1 month post-intervention was seen. Therefore,
exposure to sessions on improving injecting techniques as
part of BBV harm reduction psychosocial intervention does
not appear to encourage riskier injecting practices or fre-
quency of injecting.
Table 1 Baseline characteristics by allocation and gender
Male Female
Intervention
N = 34
Control
N = 30
Intervention
N = 18
Control
N = 17
Age
Mean (SD) 41.7 (6.81) 41.4 (7.30) 35.8 (6.06) 37.9 (8.79)
Median 42.5 42 35 37
Min, max 26, 57 22, 54 26, 48 26, 62
Number of years injecting
Mean (SD) 21.4 (8.00) 19.5 (9.01) 11.9 (7.58) 16.1 (12.14)
Median 22 19 11.5 14
Min, max 3, 36 1, 42 0, 34 0, 44
Used injecting equipment provision (IEP) in the last month 31 (91.2%) 26 (86.7%) 16 (88.9%) 16 (94.1%)
Detox/maintenance drug use 26 (76.5%) 26 (86.7%) 17 (94.4%) 16 (94.1%)
Most frequently injected drug
Heroin 15 (44.1%) 23 (76.7%) 15 (83.3%) 10 (58.8%)
Crack 1 (2.9%) 2 (6.7%) 0 (0.0%) 0 (0.0%)
Cocaine 4 (11.8%) 1 (3.3%) 0 (0.0%) 1 (5.9%)
Heroin and crack 8 (23.5%) 2 (6.7%) 3 (16.7%) 3 (17.6%)
Heroin and cocaine 1 (2.9%) 0 (0.0%) 0 (0.0%) 1 (5.9%)
Heroin and amphetamine 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (5.9%)
Speedball 1 (2.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Amphetamine 3 (8.8%) 2 (6.7%) 0 (0.0%) 1 (5.9%)
Methadone, M-cat 1 (2.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Homeless 15 (44.1%) 14 (46.7%) 8 (44.4%) 5 (29.4%)
HIV Positive 1 (2.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Hepatitis C Positive 17 (50%) 15 (50%) 5 (27.8%) 6 (35.3%)
Hepatitis B vaccinated 27 (79.4%) 22 (73.3%) 18 (100%) 14 (82.4%)
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No adverse events were recorded as a result of partici-
pating in the feasibility trial.
Health economics
Service use questionnaire
Analysis of the questionnaires identified several categories
that could be excluded from the assessment battery in a
full-randomised controlled trial. Twelve service use cat-
egories of cost were identified where >90% of responses at
all three contacts were zero. The results allow question-
naires to be revised for future use.
Costs for sessions 1, 2 and 3 are estimated for each of
the treatment centres (Table 5). Cost per patient is at-
tributed to the attendee and then the cost per session
summed to derive a total treatment cost. Total patient
treatment costs are derived by summing the costs of the
sessions attended (maximum = 3).
Mean cost was £58.17 for patients attending one
session, £148.54 for those attending two sessions and
£270.67 for those attending all three sessions in the
intervention group. Control cost per patient was
£0.86. In a pragmatic setting, these sessions would be
Table 2 Trial outcomes (total—groups as randomised)
Intervention Control
Baseline End of intervention 1 month post-intervention Baseline End of intervention 1 month post-intervention
N = 52 N = 24 N = 22 N = 47 N = 27 N = 23
Injecting risk practicesa
Mean (SD) 2.5 (2.44) 1.9 (2.16) 1.7 (2.82) 2.7 (2.93) 2.6 (2.69) 2.6 (3.20)
Median (min, max) 2 (0, 9) 1 (0, 9) 1 (0, 9) 1 (0, 9) 1 (0, 9) 1 (0, 9)
Sexual risk behavioursb
Mean (SD) 3.8 (2.08) 4.3 (1.31) 4.4 (1.92) 3.8 (1.80) 3.7 (1.98) 3.1 (1.73)
Median (min, max) 5 (0, 7) 4.5 (2, 7) 5 (0, 7) 4 (0, 7) 4 (0, 6) 3 (0, 6)
Self-efficacyc
Mean (SD) 24.1 (4.76) 24.8 (3.23) 25.3 (3.24) 23.9 (4.75) 23.7 (5.55) 25.0 (5.26)
Median (min, max) 25 (10, 31) 26 (17, 31) 25 (17, 32) 23 (16, 32) 23 (14, 32) 25 (11, 32)
HIV transmission knowledged
Mean (SD) 10.4 (2.53) 11.3 (1.92) 11.4 (1.59) 10.5 (2.23) 11.3 (1.98) 11.1 (2.19)
Median (min, max) 11 (4, 14) 11.5 (7, 14) 12 (7, 14) 11 (4, 14) 12 (6, 14) 12 (4, 14)
HCV transmission knowledgee
Mean (SD) 23.8 (3.98) 24.9 (3.49) 24.2 (3.75) 24.8 (3.15) 25.1 (2.18) 24.3 (2.99)
Median (min, max) 24.5 (13, 30) 26 (14, 29) 24 (15, 29) 25 (20, 29) 25 (20, 29) 25 (14, 28)
HBV transmission knowledgef
Mean (SD) 10.2 (3.01) 11.1 (2.10) 11.0 (2.42) 10.4 (2.45) 10.6 (2.40) 10.0 (2.70)
Median (min, max) 11 (0, 14) 11 (7, 14) 11 (7, 15) 11 (4, 14) 11 (6, 14) 11 (3, 14)
Withdrawal preventiong
Mean (SD) 6.2 (4.05) 6.5 (4.19) 5.8 (3.94) 6.9 (4.32) 6.3 (4.42) 5.6 (3.45)
Median (min, max) 6 (0, 19) 6 (0, 17) 6 (0, 13) 7 (0, 17) 4 (0, 17) 5 (0, 15)
Motivation to change (for self)h
Mean (SD) 4.5 (0.83) 4.5 (0.66) 4.6 (0.49) 4.4 (0.80) 4.7 (0.45) 4.6 (0.58)
Median (min, max) 5 (2, 5) 5 (3, 5) 5 (4, 5) 5 (2, 5) 5 (4, 5) 5 (3, 5)
Motivation to change (for others)h
Mean (SD) 4.4 (0.82) 4.3 (0.70) 4.5 (0.51) 4.4 (0.85) 4.9 (0.36) 4.7 (0.54)
Median (min, max) 5 (2, 5) 4 (3, 5) 4.5 (4, 5) 5 (0, 5) 5 (4, 5) 5 (3, 5)
aRange: 0–9 (higher number = more risk events)
bRange: 0–7 (higher number = more risk behaviours)
cRange: 8–32 (higher score = greater self-efficacy)
dRange: 0–14 (higher score = better knowledge)
eRange: 0–31 (higher score = better knowledge)
fRange: 0–15 (higher score = better knowledge)
gRange: 0–20 (higher score = better prevention tactics)
hRange: 0–5 (higher score = more motivation)
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delivered to more patients, thus reducing the mean
per session training cost.
Health-related quality of life
EQ-5D-5 L scores were valued using the social tariff [36]
at the three time points using paired analysis (Table 6).
The tariff provides utility values from a population sur-
vey whereby values for each health state are given a util-
ity score; hence, these scores reflect the population
preferences for health state values.
Baseline and control showed increases in scores on
EQ-5D-5L across the time period. EQ-5D-5L scores in
both groups improved from baseline through the two
follow-ups showing potential for health improvement
and associated QALY gains. Differences between groups
should be treated with caution due to the small sample
size. Differences in the changes between groups were
not significant, for the change baseline to the end of the
intervention the mean difference between groups was
0.05 (95% CI: −0.08, 0.17) and from end of the interven-
tion to 1 month post-intervention the difference between
Table 3 Trial outcomes (total—groups by compliance)
Attended at least one intervention session Attended none of the intervention sessions
Baseline End of intervention 1 month post-intervention Baseline End of intervention 1 month post-intervention
N = 20 N = 14 N = 16 N = 79 N = 37 N = 29
Injecting risk practicesa
Mean (SD) 2.3 (2.45) 1.7 (2.40) 1.4 (2.40) 2.6 (2.73) 2.5 (2.46) 2.6 (3.28)
Median (min, max) 1 (0, 9) 1 (0, 9) 1 (0, 9) 1.5 (0, 9) 1 (0, 9) 1 (0, 9)
Sexual risk behavioursb
Mean (SD) 4.1 (2.04) 4.3 (1.07) 3.9 (1.89) 3.8 (1.92) 3.9 (1.90) 3.7 (1.97)
Median (min, max) 5 (0, 7) 4 (3, 6) 4 (0, 7) 4 (0, 7) 4 (0, 7) 4 (0, 7)
Self-efficacyc
Mean (SD) 23.3 (5.14) 25.1 (3.12) 25.9 (3.47) 24.2 (4.64) 23.9 (5.04) 24.7 (4.76)
Median (min, max) 24.5 (12, 31) 26.5 (21, 31) 25.5 (17, 32) 24 (10, 32) 24 (14, 32) 25 (11, 32)
HIV transmission knowledged
Mean (SD) 10.8 (2.22) 11.9 (1.23) 11.4 (1.59) 10.4 (2.43) 11.1 (2.11) 11.1 (2.08)
Median (min, max) 11 (7, 14) 12 (10, 14) 12 (7, 14) 11 (4, 14) 11 (6, 14) 12 (4, 14)
HCV transmission knowledgee
Mean (SD) 23.5 (3.78) 26.1 (2.53) 24.1 (3.55) 24.5 (3.59) 24.6 (2.89) 24.4 (3.06)
Median (min, max) 24 (15, 29) 26.5 (20, 29) 24 (15, 29) 25 (13, 30) 25 (14, 29) 25 (14, 29)
HBV transmission knowledgef
Mean (SD) 10.3 (2.45) 11.1 (2.48) 11.1 (2.72) 10.3 (2.83) 10.7 (2.19) 10.2 (2.51)
Median (min, max) 11 (5, 13) 11.5 (7, 14) 11.5 (7, 15) 11 (0, 14) 11 (6, 14) 11 (3, 14)
Withdrawal preventiong
Mean (SD) 5.4 (3.36) 6.5 (4.26) 5.9 (4.13) 6.8 (4.32) 6.4 (4.34) 5.6 (3.45)
Median (min, max) 5 (0, 12) 6.5 (1, 17) 6 (0, 13) 7 (0, 19) 6 (0, 17) 6 (0, 15)
Motivation to change (for self)h
Mean (SD) 4.4 (0.82) 4.5 (0.52) 4.6 (0.51) 4.4 (0.81) 4.7 (0.58) 4.7 (0.55)
Median (min, max) 5 (2, 5) 4.5 (4, 5) 5 (4, 5) 5 (2, 5) 5 (3, 5) 5 (3, 5)
Motivation to change (for others)h
Mean (SD) 4.4 (0.59) 4.2 (0.70) 4.4 (0.51) 4.4 (0.88) 4.8 (0.49) 4.7 (0.53)
Median (min, max) 4 (3, 5) 4 (3, 5) 4 (4, 5) 5 (1, 5) 5 (3, 5) 5 (3, 5)
aRange: 0–9 (higher number = more risk events)
bRange: 0–7 (higher number = more risk behaviours)
cRange: 8–32 (higher score = greater self-efficacy)
dRange: 0–14 (higher score = better knowledge)
eRange: 0–31 (higher score = better knowledge)
fRange: 0–15 (higher score = better knowledge)
gRange: 0–20 (higher score = better prevention tactics)
hRange: 0–5 (higher score = more motivation)
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groups was 0.11 (95% CI: −0.11, 0.32). We do not present
quality-adjusted life years due to the short follow-up and
the expectation that health utility gains would become
evident over a period longer than 1 month.
Health and social resources used
Although wider NHS costs, social costs and criminal
justice costs also showed a reduction from baseline
through follow-up periods, there were no significant dif-
ferences between groups at any time point (Table 7).
Health care and criminal justice costs were also assessed
at baseline and follow-up by compliance, but there were
no significant differences based on whether a patient
had attended one or more treatment sessions compared
to those who had attended no sessions.
Acceptability of the PROTECT intervention
Intervention group participants who attended the
PROTECT sessions rated the sessions highly, reporting
they had gained valuable knowledge on blood-borne
virus transmission, safer drug use, hygiene and handwashing,
cleaning equipment and preparing for risk situations
such as withdrawal. To improve the PROTECT inter-
vention, participants suggested making it more visual,
interactive and incorporating more practical instruction
around injecting technique and injecting sites. It was
also suggested that the videos illustrating the side ef-
fects of injecting should be more graphic and feature
real people rather than animations.
Facilitators who delivered the PROTECT intervention
suggested delivering the training event over 2 days, with
equal time devoted to each of the three PROTECT
sessions, incorporating opportunities for mock delivery.
They appreciated peer educators being involved in the
training event and that their input had been incorpo-
rated into the final version of the PROTECT manual.
The sessions were rated highly and being involved in the
intervention had improved knowledge and led to changes
in their practice with clients from IEP. Session 1 was
thought too lengthy and facilitators were less comfortable
delivering the didactic parts and discussing sexual risk
behaviour. Making the intervention more interactive and
Table 4 Summary of mean group differences for outcome measuresi
Analysis by randomised groups (ITT) Analysis by attendance of at least one
intervention session
Mean 95% CI 80% CI Mean 95% CI 80% CI
Injecting risk practicesa End of intervention −0.45 −1.50 to 0.61 −1.14 to 0.24 −0.52 −1.78 to 0.74 −1.35 to 0.30
1 month post-intervention −0.25 −1.33 to 0.82 −0.96 to 0.45 −0.25 −1.51 to 1.01 −1.08 to 0.57
Sexual risk behavioursb End of intervention 0.57 −0.20 to 1.34 0.06 to 1.07 0.08 −0.85 to 1.02 −0.53 to 0.70
1 month post-intervention 1.26 0.43 to 2.08 0.71 to 1.80 0.13 −0.80 to 1.06 −0.48 to 0.74
Self-efficacyc End of intervention 1.17 −0.71 to 3.05 −0.06 to 2.40 2.20 0.02 to 4.38 0.77 to 3.62
1 month post-intervention 0.08 −1.90 to 2.07 −1.22 to 1.38 1.65 −0.51 to 3.82 0.24 to 3.07
HIV transmission knowledged End of intervention −0.06 −0.88 to 0.75 −0.60 to 0.47 0.04 −0.91 to 0.99 −0.58 to 0.66
1 month post-intervention 0.18 −0.70 to 1.06 −0.39 to 0.76 −0.07 −1.00 to 0.87 −0.68 to 0.55
HCV transmission knowledgee End of intervention 0.16 −1.37 to 1.68 −0.84 to 1.15 2.13 0.41 to 3.85 1.01 to 3.26
1 month post-intervention 0.12 −1.52 to 1.75 −0.96 to 1.19 0.30 −1.40 to 1.99 −0.81 to 1.41
HBV transmission knowledgef End of intervention 0.79 −0.31 to 1.89 0.07 to 1.51 0.79 −0.51 to 2.08 −0.06 to 1.63
1 month post-intervention 0.75 −0.41 to 1.91 −0.01 to 1.51 0.88 −0.41 to 2.18 0.03 to 1.73
Withdrawal preventiong End of intervention 0.28 −1.37 to 1.93 −0.80 to 1.36 0.38 −1.54 to 2.31 −0.88 to 1.64
1 month post-intervention 1.41 −0.34 to 3.17 0.26 to 2.57 1.83 −0.10 to 3.76 0.57 to 3.09
Motivation to change (for self)h End of Intervention −0.20 −0.47 to 0.07 −0.38 to −0.03 −0.21 −0.52 to 0.09 −0.42 to −0.01
1 month post-intervention −0.01 −0.30 to 0.28 −0.20 to 0.18 −0.21 −0.51 to 0.10 −0.41 to −0.01
Motivation to change (for others)h End of intervention −0.40 −0.67 to-0.13 −0.58 to −0.22 −0.53 −0.84 to −0.23 −0.73 to −0.33
1 month post-intervention −0.14 −0.43 to 0.15 −0.33 to 0.05 −0.29 −0.59 to 0.01 −0.49 to −0.10
aRange: 0–9 (higher number = more risk events)
bRange: 0–7 (higher number = more risk behaviours)
cRange: 8–32 (higher score = greater self-efficacy)
dRange: 0–14 (higher score = better knowledge)
eRange: 0–31 (higher score = better knowledge)
fRange: 0–15 (higher score = better knowledge)
gRange: 0–20 (higher score = better prevention tactics)
hRange: 0–5 (higher score = more motivation)
iMean differences represent the estimated mean group difference following regression analysis adjusted for outcome at baseline, gender and recruitment site;
Positive mean difference = higher score in the intervention arm, negative mean difference = higher score in the control arm
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including specialist workers for specific components
(e.g. injecting instructors, BBV nurses or sexual health
practitioners) were suggested improvements. Other
potential modes of delivery were delivery in bite-size
pieces to clients, developing as an app or QR scanner,
or as an online resource for staff training. Preparedness
plans could also be incorporated into clients’ care plans.
Identified key target groups were new referrals to treat-
ment, new injectors, sex workers, people who inject who
engage in chemsex, ie. the use of drugs (most commonly
crystal methamphetamine, mephedrone and gammaydroxy-
butrate/gamma-butyrolactone), by men who have sex with
men to facilitate or enhance sexual activity.
Discussion
We explored the feasibility of a three-session, gender-
specific psychosocial group intervention to reduce BBV
transmission behaviours among PWID which included
skills to improve injecting techniques and thus vein care,
and strategies to avoid and plan for risk situations that
PWID had themselves identified within in-depth inter-
views undertaken to inform the intervention develop-
ment (see the “Methods” section).
Although the resultant intervention was acceptable to
both facilitators and attending participants and 57% of
eligible participants agreed to be randomised, suggesting
support for addressing BBV risk behaviours among
PWID, there were considerable difficulties recruiting
particular groups of PWID, mainly women and new in-
jectors. One potential way to improve recruitment could
have been to use chain or snowball sampling, rather
than researcher recruitment, where recruited partici-
pants are encouraged to recruit members of their net-
works to the study. A previous survey in Wales
suggested individuals whose main source of needles and
syringes was secondary distribution were more likely to
be younger and more recent onset injectors; this might
explain the difficulty in recruiting newer and younger in-
jectors [37]. Research suggests that women are more
likely than men to face additional barriers to accessing
and attending treatment for drug use including family
and childcare responsibilities, shame or fear that their
children will be removed [38, 39]. Observations from re-
searchers suggest that male partners often accompanied
women to the harm reduction services (including pre-
vention, treatment and IEP). The prevalence of intimate
partner violence victimisation among female drug users
is high [16]; therefore, it is possible that in some cases,
Table 5 Intervention and control costs per session by centre
Intervention session costs
Total cost Patients
attending
Cost per
patient
Cost excl.
training
London
Session 1 £349.02 6 £58.17 £30.21
Session 2 £333.35 5 £66.67 £33.12
Session 3 £333.20 5 £66.64 £33.09
London (2)
Session 1 £316.56 2 £158.28 £74.39
Session 2 £323.43 3 £107.81 £51.89
Session 3 £316.44 2 £158.22 £74.33
Scotland
Session 1 £310.83 3 £103.61 £47.69
Session 2 £310.38 3 £103.46 £47.54
Session 3 £308.80 2 £154.40 £70.51
Wales
Session 1 £318.48 6 £53.08 £25.11
Session 2 £313.16 4 £78.29 £36.55
Session 3 £319.38 6 £53.23 £53.23
Control cost
Cost item Unit cost
Staff time £0.81
Leaflet £0.05
Cost per patient £0.86
Table 6 EQ-5D-5 L tariff scores at baseline and follow-up
EQ-5D-5 L tariff score (s.d.)
Baseline End of
intervention
1 month post-intervention
Control 0.617 (0.323)
N = 47
0.646 (0.314)
N = 47
0.788 (0.258)
N = 47
Intervention 0.672 (0.247)
N = 52
0.754 (0.193)
N = 52
0.775 (0.256)
N = 52
EQ-5D-5 L changes
Baseline to End of intervention End of intervention to 1 month post-intervention
Control +0.0738 (0.216)
N = 26
+0.1420 (0.375)
N = 17
Intervention +0.0273 (0.233)
N = 24
+0.0369 (0.232)
N = 17
Gilchrist et al. Harm Reduction Journal  (2017) 14:14 Page 11 of 15
male partners prevented women from entering the
study. Women-only treatment programmes are recom-
mended and may show improved drug use outcomes
[40]; however, interventions and services need to be cog-
nisant of the potential role of intimate partners in acces-
sing treatment.
The proportion attending at least one session in our
study was low with just 38% overall attending at least
one session (44% of males and 28% of females). While
our adherence rates are lower than previous trials of
behavioural group interventions to address BBV among
PWID (range 56–86%) [41–44], these trials recruited
participants entering or engaged in drug treatment which
may account for the difference. All of our participants had
injected drugs within the past 30 days and 44% were
homeless. Similar to other trials, we found that PWID
who were homeless or who injected more frequently were
less likely to participate or be followed up [42, 45]. Despite
gender-specific sessions being offered [46], women were
less likely to attend at least one intervention session than
men in our study. Potential reasons for this were previ-
ously discussed.
Although the findings suggest that the PROTECT
intervention has the potential to positively influence
some PWID BBV risk behaviour, non-attendance at the
intervention at the York site substantially influenced the
results, highlighting the need for flexible delivery of the
intervention content to ensure wider reach. Intervention
delivery proved more feasible in London than the other
sites, with high attendance at the intervention and higher
follow-up rates. Participants from Glasgow and York
reported higher levels of homelessness, and participants
had injected for a greater number of days and used more
needles from an IEP, which may have contributed towards
lower attendance rates. In addition, text message re-
minders were sent about session times and dates from the
service (reported preference of participants) at the York
site; whereas in the other sites, the researcher contacted
participants by telephone to remind them a day in ad-
vance plus a reminder text on the day. Moreover, staff
from the local Clinical Research Network were responsible
for recruitment and follow-up of participants (due to re-
searcher leaving); whereas in other sites, participants had
contact with the same named researcher throughout, with
this established relationship possibly contributing to
increased attendance. In addition, reimbursement for
travel costs (bus tickets), time and contingency man-
agement were paid in cash in the London site versus
high street vouchers at the other three sites and peer-
educators co-facilitated the intervention in the London
site only.
Overall, recruitment and retention rates achieved in
this feasibility trial lead us to conclude that progression
to a full trial is not recommended. There are many factors
that may have contributed to the different uptake and
retention across sites, and therefore, it is not possible to
provide a definitive explanation of the differences in rates
reported. However, it appears that the complex needs of
many PWID may have limited engagement of those
potentially most at risk of engaging in BBV transmission
behaviours (e.g. homeless PWID, more frequent injectors,
crack use).
The importance of management and of service staff
buy-in was stressed by the researchers; presenting the
study at staff meetings was used in some settings. In
addition, facilitators valued being involved in the devel-
opment of the intervention. Training of intervention
facilitators should be delivered locally (we carried this
out centrally in London creating challenges for more
distantly located staff ) and we recommend that suffi-
cient time be allocated to allow quality assurance of the
delivery of the intervention, before the intervention is
delivered in practice. Identifying sites that have previ-
ously been involved in similar research may facilitate
trial implementation as the service will be familiar with
what involvement in research studies and trials entails.
Table 7 Wider health care, criminal justice and societal costs (2014/5 prices) mean cost (s.d.) per patient
Baseline End of intervention 1 month post-intervention
Intervention Control Intervention Control Intervention Control
Total wider health care Cost £1109
(1696.14)
£1257
(2177.61)
£705
(673.39)
£997
(786.04)
£662
(682.47)
£1466
(2885.66)
Difference between groups £148
95% CI: (−657.94, 954.54)
£292
95% CI: (−137.81, 721.34)
£804
95% CI: (−611.92, 2220.61)
Total criminal justice cost £1239
(2581.51)
£1284
(3953.47)
£439
(2060.80)
£289
(1348.13)
£236
(1053.86)
£521
(1465.97)
Difference between groups £45
95% CI: (−1344.95, 1434.14)
−£151
95% CI: (−1191.45, 890.34)
£285
95% CI: (−520.06, 1091.05)
Total social cost £2489
(3397.65)
£2494
(4498.24)
£1194
(2178.38)
£1328
(1563.11)
£908
(1279.79)
£1909
(3077.46)
Difference between groups £5
95% CI: (−2107.85, 2117.58)
£134
95% CI: (−1034.59, 1303.28)
£1001
95% CI: (−662.53, 2665.44)
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The content of the intervention was rated highly by
facilitators and intervention participants alike and there
was support for addressing symbiotic goals, planning for
risk behaviours and teaching injecting skills to PWID
[47–49]. Indeed some intervention participants stressed
the need for more practical assistance on injecting tech-
nique, including observation and feedback on their own
injecting technique. Facilitators felt that the manual
could be improved by being more flexible, allowing facil-
itators to cover the information in each section without
having to follow the text verbatim. Both facilitators and
participants felt the intervention could be more visual
and interactive. Making it available online and including
information on novel psychoactive substances was con-
sidered a way of making the intervention more relevant
and attractive to younger people.
For those participants who attended the intervention
sessions, all candidate outcome measures had very good
completion rates. The number of injecting risk practices,
and self-efficacy in particular, showed improvements in
the intervention group that were maintained up to 1 month
follow-up. These outcomes might be considered in a larger
scale study in the future. BBV transmission knowledge was
more likely to show short term improvements only,
whereas withdrawal prevention questions had only lim-
ited applicability in this study population.
A meta-analysis found that the incidence of HCV re-
infection following successful treatment for HCV among
PWID was 2.4/100 per year, and 6.4/100 per year among
those who reported injecting drug use post sustained
viral response (SVR) [8]. Although there is low risk of
reinfection following successful treatment for HCV, a
large, cohort study conducted in Scotland found that
despite achieving the optimal treatment outcome, a
significant minority of PWID continued to inject post-
SVR at an intensity which lead to either hospitalisation or
death and increased risk of reinfection [35]. These findings
highlight that “harm reduction interventions aimed at re-
ducing the risk of HCV transmission should also continue
to be promoted once treatment ceases” [50].
Conclusions
While the intervention showed the potential to positively
influence BBV risk behaviours, the findings demonstrate
that a future definitive RCT of the PROTECT interven-
tion is not currently feasible in the UK. Despite this, con-
siderable and valuable insight has been obtained showing
the need for a greater embedding of BBV risk reduction in
the work of substance misuse services and highlights an
urgent unmet health need for PWID. Furthermore, the
research provides a body of evidence as to how this
might best be achieved, and has generated important
learning about the feasibility, delivery and implementation
of the PROTECT intervention which should inform future
studies in the field.
Future studies could consider the use of “chain referral
sampling” where existing study participants recruit future
participants from among their acquaintances to target
participants who may be hidden or difficult to reach for
researchers. Participants who assist with the recruitment
of other participants would be rewarded for every add-
itional participant they helped recruit. All the participating
harm reduction services suggested there was benefit in
refining the intervention further by adapting it for delivery
in specific settings (e.g. IEP, pharmacy IEP, prison) and to
specific groups of PWID including those living in home-
less hostels, people receiving opiate substitution therapy,
young injectors when they are transferred from adolescent to
adult addiction services, steroid injectors, those engaged in
chemsex and those injecting novel psychoactive substances.
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